Characterization of Severe Asthma Worldwide Data From the International Severe Asthma Registry

被引：245

作者：

Wang, Eileen ^{[1
,2
]}

Wechsler, Michael E. ^{[3
]}

Tran, Trung N. ^{[4
]}

Heaney, Liam G. ^{[5
,6
]}

Jones, Rupert C. ^{[7
]}

Menzies-Gow, Andrew N. ^{[8
,9
]}

Busby, John ^{[5
,6
]}

Jackson, David J. ^{[10
,11
,12
]}

Pfeffer, Paul E. ^{[13
,14
]}

Rhee, Chin Kook ^{[15
]}

Cho, You Sook ^{[16
]}

Canonica, G. Walter ^{[17
,18
]}

Heffler, Enrico ^{[17
,18
]}

Gibson, Peter G. ^{[19
,20
]}

Hew, Mark ^{[21
,22
]}

Peters, Matthew ^{[23
]}

Harvey, Erin S. ^{[19
,20
]}

Alacqua, Marianna ^{[24
]}

Zangrilli, James ^{[4
]}

Bulathsinhala, Lakmini ^{[25
]}

Carter, Victoria A. ^{[25
]}

Chaudhry, Isha ^{[25
]}

Eleangovan, Neva ^{[25
]}

Hosseini, Naeimeh ^{[25
]}

Murray, Ruth B. ^{[25
]}

Price, David B. ^{[25
,26
,27
]}

机构：

[1] Natl Jewish Hlth, Dept Med, Div Allergy & Clin Immunol, Denver, CO USA

[2] Univ Colorado Hosp, Dept Internal Med, Div Allergy & Clin Immunol, Aurora, CO USA

[3] Natl Jewish Hlth, Dept Med, NJH Cohen Family Asthma Inst, Denver, CO USA

[4] AstraZeneca, Gaithersburg, MD USA

[5] Queens Univ Belfast, UK Severe Asthma Network, Belfast, Antrim, North Ireland

[6] Queens Univ Belfast, Natl Registry, Belfast, Antrim, North Ireland

[7] Univ Plymouth, Fac Med & Dent, Plymouth, Devon, England

[8] Royal Brompton & Harefield NHS Fdn Trust, UK Severe Asthma Network, London, England

[9] Royal Brompton & Harefield NHS Fdn Trust, Natl Registry, London, England

[10] Guys & St Thomas NHS Trust, UK Severe Asthma Network, London, England

[11] Guys & St Thomas NHS Trust, Natl Registry, London, England

[12] Kings Coll London, Div Asthma Allergy & Lung Biol, London, England

[13] Barts Hlth NHS Trust, UK Severe Asthma Network, London, England

[14] Queen Mary Univ London, London, England

[15] Catholic Univ Korea, St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm Allergy & Crit Care Me, Seoul, South Korea

[16] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Allergy & Clin Immunol,Coll Med, Seoul, South Korea

[17] Humanitas Univ & Res Hosp, Personalized Med Asthma & Allergy Clin, Milan, Italy

[18] SANI, Milan, Italy

[19] Univ Newcastle, Prior Res Ctr Hlth Lungs, Australian Severe Asthma Network, Newcastle, NSW, Australia

[20] John Hunter Hosp, Hunter Med Res Inst, Dept Resp & Sleep Med, New Lambton Hts, NSW, Australia

[21] Alfred Hlth, Allergy Asthma & Clin Immunol Serv, Melbourne, Vic, Australia

[22] Monash Univ, Publ Hlth & Prevent Med, Melbourne, Vic, Australia

[23] Concord Hosp, Dept Thorac Med, Sydney, NSW, Australia

[24] AstraZeneca Plc, Cambridge, England

[25] Optimum Patient Care Global Ltd, Cambridge, England

[26] Observat & Pragmat Res Inst, Singapore, Singapore

[27] Univ Aberdeen, Ctr Acad Primary Care, Div Appl Hlth Sci, Aberdeen, Scotland

来源：

CHEST | 2020年 / 157卷 / 04期

关键词：

biologics; comorbidity; eosinophils; FENO; IgE; CARE RESOURCE USE; EOSINOPHILIC ASTHMA; REFRACTORY ASTHMA; ALLERGIC-ASTHMA; OMALIZUMAB; COSTS;

D O I：

10.1016/j.chest.2019.10.053

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

BACKGROUND Clinical characteristics of the international population with severe asthma are unknown. Intercountry comparisons are hindered by variable data collection within regional and national severe asthma registries. We aimed to describe demographic and clinical characteristics of patients treated in severe asthma services in the United States, Europe, and the Asia-Pacific region. METHODS The International Severe Asthma Registry retrospectively and prospectively collected data in patients with severe asthma >= 18 years old), receiving Global Initiative for Asthma (GINA) Step 5 treatment or with severe asthma remaining uncontrolled at GINA Step 4. Baseline demographic and clinical data were collected from the United States, United Kingdom, South Korea, Italy, and the Severe Asthma Web-based Database registry (including Australia, Singapore, and New Zealand) from December 2014 to December 2017. RESULT We included 4,990 patients. Mean (SD) age was 55.0 (15.9) years, and mean (SD) age at asthma onset was 30.7 (17.7) years. Patients were predominantly female (59.3%) and white (72.6%), had never smoked (60.5%), and were overweight or obese (70.4%); 34.9% were at GINA Step 5; and 57.2% had poorly controlled disease. A total of 51.1% of patients were receiving regular intermittent oral corticosteroids, and 25.4% were receiving biologics (72.6% for those at GINA Step 5). Mean (SD) exacerbation rate was 1.7 (2.7) per year. Intercountry variation was observed in clinical characteristics, prescribed treatments, and biomarker profiles. CONCLUSION Using a common data set and definitions, this study describes severe asthma characteristics of a large patient cohort included in multiple severe asthma registries and identifies country differences. Whether these are related to underlying epidemiological factors, environmental factors, phenotypes, asthma management systems, treatment access, and/ or cultural factors requires further study.

引用

页码：790 / 804

页数：15

共 51 条

[1] LUNG-FUNCTION TESTING - SELECTION OF REFERENCE VALUES AND INTERPRETATIVE STRATEGIES [J].

不详 .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (05) :1202-1218

[2]

[Anonymous], 2018, GLOB STRAT ASTHM MAN

[3]

[Anonymous], [No title captured]

[4]

[Anonymous], [No title captured]

[5]

[Anonymous], 2019, DIFF TO TREAT SEV AS

[6]

[Anonymous], [No title captured]

[7]

[Anonymous], [No title captured]

[8] Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma [J].

Bleecker, Eugene R. ;

Wechsler, Michael E. ;

FitzGerald, J. Mark ;

Menzies-Gow, Andrew ;

Wu, Yanping ;

Hirsch, Ian ;

Goldman, Mitchell ;

Newbold, Paul ;

Zangrilli, James G. .

EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (04)

[9]

British Thoracic Society, BTS/SIGN British Guideline on the Management of Asthma 2019

[10]

Bulathsinhala L, 2019, J ALLERGY CLIN IMMUN, V7

← 1 2 3 4 5 6 →